Evolution Wealth Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Evolution Wealth Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24	Closed	-$4K	–	658
2021 Q3	$4K	Sell	24 -46	-66%	-$7.4K	﹤0.01%	584
2021 Q2	$11K	Sell	70 -16	-19%	-$2.57K	﹤0.01%	399
2021 Q1	$15K	Sell	86 -6	-7%	-$1.19K	﹤0.01%	348
2020 Q4	$20K	Sell	92 -87	-49%	-$18.8K	﹤0.01%	270
2020 Q3	$30K	Sell	179 -104	-37%	-$14.2K	0.01%	233
2020 Q2	$32K	Hold	283	–	–	0.01%	168
2020 Q1	$22K	Buy	283 +78	+38%	+$7K	0.01%	148
2019 Q4	$26K	Sell	205 -19	-8%	-$1.83K	0.01%	205
2019 Q3	$17K	Buy	224 +23	+11%	+$2.16K	0.01%	120
2019 Q2	$21K	Buy	+201	New	+$15.6K	0.01%	126

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Evolution Wealth Advisors's MRTX Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 24 shares — an estimated $4K sold.

Evolution Wealth Advisors first reported a position in MRTX in Q2 2019 and held it in 10 quarters. The position peaked at $32K in Q2 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

Evolution Wealth Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 24 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $4K.
Evolution Wealth Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
Evolution Wealth Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $32K in Q2 2020.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.